Blood Granzyme B Surge Signals Nivolumab Response in Advanced Lung Cancer
A prospective study demonstrates that longitudinal increases in circulating Granzyme B and activated cytotoxic lymphocytes track therapeutic response and survival ...
A prospective study demonstrates that longitudinal increases in circulating Granzyme B and activated cytotoxic lymphocytes track therapeutic response and survival ...
The Alliance for Clinical Trials in Oncology is highlighting eight ongoing clinical studies investigating new detection, treatment, and survivorship strategies ...
A retrospective study of 60 Chinese patients with metastatic renal cell carcinoma receiving first-line ipilimumab plus nivolumab showed progression-free survival ...
Clinicians report a rare case of delayed drug-induced interstitial lung disease developing over three months after neoadjuvant chemoimmunotherapy for lung ...
An international multidisciplinary Delphi consensus achieved 80 percent agreement across 40 clinical statements to standardize diagnostic, surgical, and systemic care ...
An observational economic analysis of the NIH All of Us Research Program found that third-line immunotherapy for advanced colorectal cancer ...
A phase 2 clinical trial found that combining regorafenib, chemotherapy, and nivolumab was safe and remodeled the tumor microenvironment in ...
Early changes in thyroid-stimulating hormone levels independently predicted subsequent immune-related hypothyroidism in cancer patients treated with nivolumab.
Clinicians documented the rare concurrent emergence of rheumatoid arthritis and Sjögren's syndrome in a patient receiving nivolumab for recurrent gastric ...
A longitudinal immune monitoring study showed that combining tinostamustine with nivolumab was linked to preserved adaptive immune competence and antigen-specific ...
A single case report shows that pathologic complete response after neoadjuvant chemoimmunotherapy did not restore a safe dissection plane in ...
A new open-access review in Discover Oncology surveys the key signaling pathways in oral squamous cell carcinoma and the targeted ...
A phase II trial reports 11.9-month median overall survival with CIMAvax-EGF plus nivolumab in previously treated advanced NSCLC, with the ...
A study of 3,243 Japanese patients found that observed fixed-dose nivolumab billing was a median of 89,540 yen higher per ...
Long-term results from the phase 2 NICHE-2 trial show that none of 111 patients with dMMR colon cancer treated with ...
A multi-cohort re-analysis of melanoma transcriptomes and single-cell immune data links coordinated checkpoint-gene expression to longer overall survival, treatment-related immune ...
A retrospective Nepalese cohort of 31 patients associated 20- or 40-milligram nivolumab with responses across advanced cancers, but uncontrolled evidence ...
A Japanese case report documents a remarkable sustained response to nivolumab in a patient whose stage III melanoma recurred as ...
A case report from Gunma University describes severe autoimmune hemolytic anemia triggered by nivolumab plus ipilimumab for melanoma that resolved ...
Two UCLA-led studies identify T-cell infiltration as the key to effective glioblastoma immunotherapy and introduce a preclinical model that recreates ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.